To see the other types of publications on this topic, follow the link: Bid Optimization.
Journal articles on the topic 'Bid Optimization'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Bid Optimization.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Balakrishnan, Raju, and Rushi P. Bhatt. "Real-Time Bid Optimization for Group-Buying Ads." ACM Transactions on Intelligent Systems and Technology 5, no. 4 (January 23, 2015): 1–21. http://dx.doi.org/10.1145/2532441.
Full text
2
Milano, Michela, and Alessio Guerri. "Bid evaluation in combinatorial auctions: optimization and learning." Software: Practice and Experience 39, no. 13 (September 10, 2009): 1127–55. http://dx.doi.org/10.1002/spe.930.
Full text
3
Tandale, Akshaykumar, Chaitanya Shirsath, Bharat Vigne, Yash Dane, and Dr Ayub Sheikh. "Analysis & Optimization to Improve the Tedious Tendering Process in Construction Industry." International Journal for Research in Applied Science and Engineering Technology 11, no. 5 (May 31, 2023): 951–54. http://dx.doi.org/10.22214/ijraset.2023.51635.
Full textAbstract:
Abstract: This analysis and optimization study aims to improve the tedious tendering process in the construction industry. The study identifies the major challenges faced by stakeholders in the tendering process, including high administrative costs, lack of transparency, lengthy bidding periods, and inconsistencies in bid evaluation criteria. Various optimization techniques are proposed, including the use of electronic bidding platforms, standardization of bid evaluation criteria, and the implementation of a two-stage bidding process. The study concludes that implementing these optimization techniques can significantly improve the efficiency and effectiveness of the tendering process, resulting in lower costs, faster bidding periods, and increased transparency.
4
Arya, A., SPS Mathur, and M. Dubey. "Impact of emission trading and renewable energy support scheme on the optimality of generator side bidding." E3S Web of Conferences 167 (2020): 05008. http://dx.doi.org/10.1051/e3sconf/202016705008.
Full textAbstract:
As a major Green House Gases (GHG) producer, CO2 in particular, the electricity industry’s emissions have turned in to a matter of immense concern in many countries, especially in India. India’s economy and fast economic development has attracts the attention of the world. Emission trading schemes (ETS) and renewable energy support schemes (RESS) are implemented by the various developed countries to alleviate the affect of GHG emissions. In this paper, an optimization based market simulation approach is proposed with the consideration of emission trading schemes and renewable support schemes. To simulate the bidding strategy and for profit maximization, a particle swarm optimization (PSO) algorithm is used. As above problem is a multi-objective optimization problem, Where, in the first level each Genco submit the bid to the independent system operator and in the next level a optimization method is used for the determination of optimal bidding with the implementation of emission trading schemes and renewable support schemes. It is assumed that each generator should submit bid as a price taker’s in sealed auction based on pay-as-bid market clearing price mechanism. The practicability of proposed optimization method is checked by an IEEE-30 bus test system consists of six suppliers.
5
Zhu, Zhong Rong, Xin Zhe Li, and Zheng Song Wu. "Analysis on Optimization of Dividing Construction Bid-Section Based on Safety Risks." Advanced Materials Research 912-914 (April 2014): 1571–75. http://dx.doi.org/10.4028/www.scientific.net/amr.912-914.1571.
Full textAbstract:
The geological disaster prevention project is to bring the unstable and unsafe disaster bodies under control, so construction safety risk prevention of this kind of projects is of great importance. Project bid-section division is closely related to the degree of project dispersion, the frequency of monitoring visits and the project duration, and it will also have influence on project construction safety risk. According to the characteristics of geological disaster prevention projects, the paper makes a quantitative analysis of the factors that influence the construction safety. The proposed bid-section division programs are calculated and analyzed by using fuzzy entropy weight model of group decision-making, so as to determine the optimal bid-section division program based on safety risk prevention.
6
Xinyi, Yang, Chen Han, Chen Liu, Xie Ying, and Chen Bing. "Research on Intelligent Verification Technology of Bid Evaluation Results." BCP Business & Management 45 (April 27, 2023): 402–6. http://dx.doi.org/10.54691/bcpbm.v45i.4961.
Full textAbstract:
Bidding is an important procurement method. By giving full play to the advantages of bidding enterprises and carrying out open and fair competition, it has realized the effective optimization of the market economic environment and significantly improved the benefits of engineering projects. The bidding of power engineering project is to realize the fair and transparent competition among bidding units. In order to improve the standardization and fairness of bid evaluation results and solve the final control problem of power bidding, it is particularly important to do a good job in the intelligent verification of bid evaluation results. This paper mainly studies the intelligent verification technology of bidding and bid evaluation results. By studying the bidding and bid evaluation process and standards, and using information intelligent technology, this project summarizes some standard laws and models for verifying the bid evaluation results, and develops the intelligent verification tool of bid evaluation results.
7
Nuara, Alessandro, Francesco Trovò, Nicola Gatti, and Marcello Restelli. "Online joint bid/daily budget optimization of Internet advertising campaigns." Artificial Intelligence 305 (April 2022): 103663. http://dx.doi.org/10.1016/j.artint.2022.103663.
Full text
8
Yan, Fang, Yanfang Ma, Manjing Xu, and Xianlong Ge. "Transportation Service Procurement Bid Construction Problem from Less Than Truckload Perspective." Mathematical Problems in Engineering 2018 (2018): 1–17. http://dx.doi.org/10.1155/2018/1728512.
Full textAbstract:
This paper presents mixed integer programming for a transportation service procurement bid construction problem from a less than full truckload perspective, in which the bidders (carriers) generate their best bid (package) using a bundled price to maximize their utility and increase the chance of winning the business. The models are developed from both the carriers and shippers perspectives to establish a relationship between the quoted price and the likelihood of winning to assist the carriers in balancing the potential benefits and the possibility of winning the bid. An intelligent algorithm based on Particle Swarm Optimization is then designed to solve the proposed model and hypothetical data sets are used to test the effectiveness and efficiency of the proposed model and algorithm.
9
Islam, Md Mainul, and Sherif Mohamed. "Bid-Winning Potential Optimization for Concession Schemes with Imprecise Investment Parameters." Journal of Construction Engineering and Management 135, no. 8 (August 2009): 690–700. http://dx.doi.org/10.1061/(asce)co.1943-7862.0000032.
Full text
10
Kuyzu, Gültekin, Çağla Gül Akyol, Özlem Ergun, and Martin Savelsbergh. "Bid price optimization for truckload carriers in simultaneous transportation procurement auctions." Transportation Research Part B: Methodological 73 (March 2015): 34–58. http://dx.doi.org/10.1016/j.trb.2014.11.012.
Full text
11
Denkena, B., M. A. Dittrich, S. Wilmsmeier, and S. Stamm. "Optimization of delivery adherence based on capacity planning and bid pricing." Production Engineering 14, no. 3 (April 5, 2020): 309–18. http://dx.doi.org/10.1007/s11740-020-00959-8.
Full text
12
Yao, Leehter, Wei Lim, Sew Tiang, Teng Tan, Chin Wong, and Jia Pang. "Demand Bidding Optimization for an Aggregator with a Genetic Algorithm." Energies 11, no. 10 (September 20, 2018): 2498. http://dx.doi.org/10.3390/en11102498.
Full textAbstract:
Demand response (DR) is an effective solution used to maintain the reliability of power systems. Although numerous demand bidding models were designed to balance the demand and supply of electricity, these works focused on optimizing the DR supply curve of aggregator and the associated clearing prices. Limited researches were done to investigate the interaction between each aggregator and its customers to ensure the delivery of promised load curtailments. In this paper, a closed demand bidding model is envisioned to bridge the aforementioned gap by facilitating the internal DR trading between the aggregator and its large contract customers. The customers can submit their own bid as a pairs of bidding price and quantity of load curtailment in hourly basis when demand bidding is needed. A purchase optimization scheme is then designed to minimize the total bidding purchase cost. Given the presence of various load curtailment constraints, the demand bidding model considered is highly nonlinear. A modified genetic algorithm incorporated with efficient encoding scheme and adaptive bid declination strategy is therefore proposed to solve this problem effectively. Extensive simulation shows that the proposed purchase optimization scheme can minimize the total cost of demand bidding and it is computationally feasible for real applications.
13
Wang, Yun Min, Hai Long Ma, and Xi Fu Zhang. "The Design Optimization Method of Steam Turbine Cold End in Coal-Fired Power Plant." Advanced Materials Research 732-733 (August 2013): 301–5. http://dx.doi.org/10.4028/www.scientific.net/amr.732-733.301.
Full textAbstract:
The design optimization of steam turbine cold end is an important measure to ensuring safety and economic operation of the unit. Based on the universal calculation method of steam turbine output correction, considering investment cost, operation cost, cooling water expenditure and hot pollution cost, the design optimization of steam turbine cold end was carried out. An example of the domestic 300MW unit was presented to show the validity of this method. The design optimization results can be used as a foundation for the equipment selection and inviting bid documents compilation of steam turbine cold end in coal-fired power plant.
14
Wiggins, Ralphe, and John A. Tomlin. "Bid Optimization for Internet Graphical Ad Auction Systems via Special Ordered Sets." iBusiness 02, no. 03 (2010): 249–54. http://dx.doi.org/10.4236/ib.2010.23032.
Full text
15
Paul, Jomon Aliyas, and Xinfang (Jocelyn) Wang. "Robust optimization for United States Department of Agriculture food aid bid allocations." Transportation Research Part E: Logistics and Transportation Review 82 (October 2015): 129–46. http://dx.doi.org/10.1016/j.tre.2015.08.001.
Full text
16
Jain, Kavita, Akash Saxena, Ahmad M. Alshamrani, Adel Fahad Alrasheedi, Khalid Abdulaziz Alnowibet, and Ali Wagdy Mohamed. "An Amended Whale Optimization Algorithm for Optimal Bidding in Day Ahead Electricity Market." Axioms 11, no. 9 (September 5, 2022): 456. http://dx.doi.org/10.3390/axioms11090456.
Full textAbstract:
Successful privatization in other sectors leads to a restructuring in the power sector. The same practice has been adopted in the electrical industry with a deregulated electricity market (EM). This enables competition among generating companies (Genco’s) for maximizing their profit and it plays a central role. With this aim, each Genco gives a higher bid that may result in a risk of losing the opportunity to get selected at auction. The big challenge in front of a Genco is to acquire an optimal bid and this process is known as the Optimal Bidding Strategy (OBS) of a Genco. In this manuscript, a new variant of whale optimization (WOA) termed the Amended Whale Optimization Algorithm (AWOA) is proposed, to attain the OBS of thermal Genco in an EM. Once the effectiveness of new AWOA is proved on 23 benchmark functions, it is applied to five Genco strategic bidding problems in a spot market with uniform price. The results obtained from the proposed AWOA are compared with other competitive algorithms. The results reflect that AWOA outperforms in terms of the profit and convergence rate. Simulations also indicate that the proposed AWOA can successfully be used for an OBS in the EM.
17
Litjens, Carlijn H. C., Laurens F. M. Verscheijden, Elin M. Svensson, Petra H. H. van den Broek, Hedwig van Hove, Jan B. Koenderink, Frans G. M. Russel, Rob E. Aarnoutse, and Lindsey H. M. te Brake. "Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis." Antibiotics 12, no. 4 (April 3, 2023): 702. http://dx.doi.org/10.3390/antibiotics12040702.
Full textAbstract:
Linezolid is used off-label for treatment of central nervous system infections. However, its pharmacokinetics and target attainment in cranial cerebrospinal fluid (CSF) in tuberculous meningitis patients is unknown. This study aimed to predict linezolid cranial CSF concentrations and assess attainment of pharmacodynamic (PD) thresholds (AUC:MIC of >119) in plasma and cranial CSF of adults and children with tuberculous meningitis. A physiologically based pharmacokinetic (PBPK) model was developed to predict linezolid cranial CSF profiles based on reported plasma concentrations. Simulated steady-state PK curves in plasma and cranial CSF after linezolid doses of 300 mg BID, 600 mg BID, and 1200 mg QD in adults resulted in geometric mean AUC:MIC ratios in plasma of 118, 281, and 262 and mean cranial CSF AUC:MIC ratios of 74, 181, and 166, respectively. In children using ~10 mg/kg BID linezolid, AUC:MIC values at steady-state in plasma and cranial CSF were 202 and 135, respectively. Our model predicts that 1200 mg per day in adults, either 600 mg BID or 1200 mg QD, results in reasonable (87%) target attainment in cranial CSF. Target attainment in our simulated paediatric population was moderate (56% in cranial CSF). Our PBPK model can support linezolid dose optimization efforts by simulating target attainment close to the site of TBM disease.
18
Orsi, Alessandro, Ignacio Guillén-Guillamón, and Eugenio Pellicer. "Optimization of Green Building Design Processes: Case Studies within the European Union." Sustainability 12, no. 6 (March 14, 2020): 2276. http://dx.doi.org/10.3390/su12062276.
Full textAbstract:
Green buildings have recently become a key aspect of the construction field and bring along a renovation of the whole industry chain. Such changes introduce new challenges for all subjects involved, and designers are also affected by such issues, especially for the development of projects based on international green building standards. Within this scope, project management plays a key role in the optimization of the design phase. This research analyzes the design process of international projects from the project management perspective through a multiple case study approach, considering the sustainability-related tasks that negatively affect the project design development under two types of contractual approaches: Design-Build and Design-Bid-Build. It aims to identify whether the Design-Build or Design-Bid-Build process is the best solution for developing green building projects. Two case studies in Italy and two case studies in Spain are analyzed, and the effects of the project management issues are evaluated under three different points of view: Time, cost, and level of sustainability of the building. A poorly planned process for the achievement of the various green building features of the project can impact the project schedule and the budget, whereas, a poorly managed project could also negatively impact its green building features. Finally, this research also highlights the positive relationship between process integration and green building design development.
19
MADAN, DILIP B. "CONIC PORTFOLIO THEORY." International Journal of Theoretical and Applied Finance 19, no. 03 (April 21, 2016): 1650019. http://dx.doi.org/10.1142/s0219024916500199.
Full textAbstract:
Portfolios are designed to maximize a conservative market value or bid price for the portfolio. Theoretically this bid price is modeled as reflecting a convex cone of acceptable risks supporting an arbitrage free equilibrium of a two price economy. When risk acceptability is completely defined by the risk distribution function and bid prices are additive for comonotone risks, then these prices may be evaluated by a distorted expectation. The concavity of the distortion calibrates market risk attitudes. Procedures are outlined for observing the economic magnitudes for diversification benefits reflected in conservative valuation schemes. Optimal portfolios are formed for long only, long short and volatility constrained portfolios. Comparison with mean variance portfolios reflects lower concentration in conic portfolios that have comparable out of sample upside performance coupled with higher downside outcomes. Additionally the optimization problems are robust, employing directionally sensitive risk measures that are in the same units as the rewards. A further contribution is the ability to construct volatility constrained portfolios that attractively combine other dimensions of risk with rewards.
20
Cortes, Jorge, Clara Chen, Michael Mauro, Neela Kumar, Catherine Davis, and Stuart L. Goldberg. "CLO19-029: Dosing Patterns of Nilotinib Use in SIMPLICITY, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice." Journal of the National Comprehensive Cancer Network 17, no. 3.5 (March 8, 2019): CLO19–029. http://dx.doi.org/10.6004/jnccn.2018.7214.
Full textAbstract:
Introduction: Dosing patterns of nilotinib (NIL) in chronic phase chronic myelogenous leukemia (CP-CML) patients (Pts) have not been well documented outside of clinical trials. SIMPLICITY (NCT01244750) is an ongoing observational study exploring tyrosine kinase inhibitor (TKI) use in routine clinical practice among CP-CML pts receiving TKIs in the US and Europe since 2010. This analysis reports NIL dosing patterns and explores predictors of dose reductions. A subset analysis focusing on the first-line (1L) approved dose of 300 mg twice daily (BID) will also be presented. Methods: Only SIMPLICITY pts receiving 1L NIL BID (n=349/408) were included. Baseline demographics and dosing patterns (starting dose, dose changes, time to dose reduction, and duration of therapy [DoT]) were analyzed descriptively. Statistical comparisons were made using t-tests, the Mann-Whitney U test for continuous variables, and chi-square for categorical variables. Logistic regression models were used to identify factors associated with dose reductions. Results: Of the 349 pts treated with 1L NIL, 281 (80.5%) started at the standard dose of 300 mg (BID) or the 400 mg (BID) dose for imatinib-resistance/intolerance, and 37 (10.6%) and 31 pts (8.9%) started on 150‒200 mg BID and 450‒800 mg BID. European pts were more likely to start on a dose >400 mg BID than US pts (P<.0001). Pts at academic centers were more likely to start on >400 mg BID than those treated at community practices (P<.0029). Among the pts starting NIL at 300 or 400 mg (BID) in 1L, 70.9% remained on these doses; 26.6% received a dose reduction (median time to dose reduction: 80.5 days); and 2.5% received a dose increase. Median DoT with NIL was 30.4 vs 43.9 months for pts with vs without a dose reduction (P=NS). The main reason for dose reduction was intolerance (n=51; 68.9%); in 51% of pts, a specific side effect was cited. Dose reductions were more likely in patients at academic centers (odds ratio=1.996; P=.021), but not in pts experiencing baseline fatigue (OR=1.799; P=0.072). Conclusions: Most pts treated with 1L NIL were started on 300 or 400 mg (BID); however, 1 in 4 pts required a dose reduction, most often due to intolerance. Physicians at academic centers were more likely to reduce the NIL dose than those in community practices. DoT with NIL for pts who received a dose reduction was shorter than that for those who did not. These findings will aid clinical decisions on dose optimization and maintaining response, whilst improving the patient quality of life.
21
Wang, Xiaolin, and Wei Yin. "On Optimization and Adjustment of Road Line of Duozegou Bridge, the B Bid Section Road Project in the Upper Reaches of Ya-lung River." E3S Web of Conferences 136 (2019): 04059. http://dx.doi.org/10.1051/e3sconf/201913604059.
Full textAbstract:
Based on the external reconstruction project of B bid section road project in the upper reaches of Ya-lung River, this paper takes the total consideration of whole construction period control, construction risk, construction difficulty and investment saving of the Duozegou Bridge, and puts forward some optimization suggestions. From the aspects of the feasibility of the optimization, economic comparison and selection, this paper makes a deep discussion on the section of this road line, and obtains obvious results, which has won the great praise of the owner company. Meanwhile, this paper summarizes the experience for similar projects in the future, and provides reference for other similar projects at the same time.
22
Flåm, Sjur Didrik. "Generalized gradients, bid–ask spreads, and market equilibrium." Optimization 68, no. 2-3 (March 4, 2019): 579–92. http://dx.doi.org/10.1080/02331934.2019.1583752.
Full text
23
Bikeri, Adline, Christopher Muriithi, and Peter Kihato. "GENCO Optimal Bidding Strategy and Profit based Unit Commitment using Evolutionary Particle Swarm Optimization Illustrating the Effect of GENCO Market Power." International Journal of Electrical and Computer Engineering (IJECE) 8, no. 4 (August 1, 2018): 1997. http://dx.doi.org/10.11591/ijece.v8i4.pp1997-2013.
Full textAbstract:
<p>In deregulated electricity markets, generation companies (GENCOs) make unit commitment (UC) decisions based on a profit maximization objective in what is termed profit based unit commitment (PBUC). PBUC is done for the GENCOs demand which is a summation of its bilateral demand and allocations from the spot energy market. While the bilateral demand is known, allocations from the spot energy market depend on the GENCOs bidding strategy. A GENCO thus requires an optimal bidding strategy (OBS) which when combined with a PBUC approach would maximize operating profits. In this paper, a solution of the combined OBS-PBUC problem is presented. An evolutionary particle swarm optimization (EPSO) algorithm is implemented for solving the optimization problem. Simulation results carried out for a test power system with GENCOs of differing market strengths show that the optimal bidding strategy depends on the GENCOs market power. Larger GENCOs with significant market power would typically bid higher to raise market clearing prices while smaller GENCOs would typically bid lower to capture a larger portion of the spot market demand. It is also illustrated that the proposed EPSO algorithm has a better performance in terms of solution quality than the classical PSO algorithm.</p>
24
Tsegaye, Matiwos. "Efficient Procedure to Scheduling Construction Projects at the Planning Phase." Baltic Journal of Real Estate Economics and Construction Management 7, no. 1 (January 1, 2019): 60–80. http://dx.doi.org/10.2478/bjreecm-2019-0004.
Full textAbstract:
Abstract The construction industry is one of the most important activities that contributes towards the economic growth of any nation. However, the sector has been experiencing problems of cost and time overruns, particularly the problems are significant for the lowest-bid awarded construction projects in the developing countries where inappropriate planning is reported to be one of the major causes. Thus, the paper aims at developing an integrated scheduling approach for construction projects during the planning phase from a project owner’s perspective. The proposed approach integrates cost estimation and schedule in light of practical activity precedence and mathematical cost optimization using different project commencement dates. The study has shown that cost and time optimization model could yield impractical results unless double precedence relations (start-to-start plus finish-to-finish) are imposed between some activities such as trench excavation and pipe laying. It has also demonstrated that the cost and time budgeted during the planning phase would substantially deviate from actual if the planned construction start date slips from the plan, particularly for short period projects. The proposed approach demonstrated in the paper can sufficiently allow planning engineers to develop a comprehensive construction schedule so that the cost and time overruns in the lowest-bid awarded construction projects can be reduced. The paper provides empirical insights into how a robust construction schedule is developed from an owner’s perspective. Cost-time optimization and risk analysis results obtained from manual computation might reduce the reasonable accuracy of the desired cost and schedule integration unless each activity is assigned its own calendar.
25
Knežević, Goran, Zoran Baus, and Srete Nikolovski. "Short–Term Planning of Hybrid Power System." Journal of Electrical Engineering 67, no. 4 (July 1, 2016): 234–45. http://dx.doi.org/10.1515/jee-2016-0035.
Full textAbstract:
Abstract In this paper short-term planning algorithm for hybrid power system consist of different types of cascade hydropower plants (run-of-the river, pumped storage, conventional), thermal power plants (coal-fired power plants, combined cycle gas-fired power plants) and wind farms is presented. The optimization process provides a joint bid of the hybrid system, and thus making the operation schedule of hydro and thermal power plants, the operation condition of pumped-storage hydropower plants with the aim of maximizing profits on day ahead market, according to expected hourly electricity prices, the expected local water inflow in certain hydropower plants, and the expected production of electrical energy from the wind farm, taking into account previously contracted bilateral agreement for electricity generation. Optimization process is formulated as hourly-discretized mixed integer linear optimization problem. Optimization model is applied on the case study in order to show general features of the developed model.
26
Ferraz, José Euclides De Melo, and Christian Johannes Zimmer. "Inclusão de Custos de Transação Não-Lineares na Otimização Média-Variância." Brazilian Review of Finance 3, no. 2 (January 1, 2005): 195. http://dx.doi.org/10.12660/rbfin.v3n2.2005.1150.
Full textAbstract:
In this article we propose a new way to include transaction costs into a mean-variance portfolio optimization. We consider brokerage fees, bid/ask spread and the market impact of the trade. A pragmatic algorithm is proposed, which approximates the optimal portfolio, and we can show that is converges in the absence of restrictions. Using Brazilian financial market data we compare our approximation algorithm with the results of a non-linear optimizer.
27
Bâra, Adela. "Mix-generation optimization for electricity market simulation." Scientific Bulletin of Naval Academy XXIII, no. 1 (July 15, 2020): 180–85. http://dx.doi.org/10.21279/1454-864x-20-i1-023.
Full textAbstract:
Owning several types of generating units requires an optimized schedule to cover the negotiated bilateral contracts. This approach will lead to a better electricity market strategy and benefits for an electricity producer. In this paper, we will simulate the operation of five different generators including generators based on Renewable Energy Sources (such as wind turbines and photovoltaic panels) that belong to an electricity producer. The five generators are modelled considering the specificity of their type and primary energy source. For instance, for renewable energy sources, we will consider the 24-hour generation forecast. The objective function of the optimization process is to obtain an optimal loading of generators, while the constraints are related to the capacity and performance of the generators. The output consisting in a generating unit optimized operation schedule will be further used for day-ahead or balancing market bidding process. Hence, the producer will be able to adequately bid on the future electricity markets knowing the commitment of generators for negotiated bilateral contracts market. The simulations are tested for more than five generators considering the connection to a relational database where more data for generators is stored.
28
Pasquini, R., O. G. Ottmann, Y. T. Goh, D. Kim, P. E. Dorlhiac Llacer, J. F. DiPersio, H. J. Khoury, J. M. Van Tornout, A. Damokosh, and H. M. Kantarjian. "Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: One-year results of CA180–035." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 7025. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7025.
Full textAbstract:
7025 Background: Dasatinib, an oral multi-targeted kinase inhibitor of BCR-ABL and SRC family kinases, has been shown to be safe and effective at 70 mg BID in advanced phase CML and Ph(+) ALL resistant or intolerant to imatinib. QD and BID schedules were equipotent in Phase I which led to this dose-optimization study. Methods: In this Phase-III, open-label, prospective study, patients with imatinib-resistant or intolerant advanced phase CML or Ph(+) ALL were randomized to dasatinib 140 mg QD or 70 mg BID. The primary objective compared the major hematologic response (HR) rate between the 2 regimens. Dose escalation was allowed for inadequate response and dose reduction for drug toxicity. Results: From June 2005 through March 2006, 611 patients (56% male) were randomized (median age 55 years). 42% of patients received imatinib at doses >600 mg/d and 37% were treated for >3 y. Response rates, with a median follow-up of 6.5 mo (range <1 to 17 mo), are summarized in the table below. Median durations of HR and progression-free survival were 10.2 and 7.9 mo for the 140-mg QD regimen vs 12.3 and 11.7 mo in the 70-mg BID arm. Drug-related toxicities in 140-mg QD (n=304) vs 70-mg BID (n=305) arms, respectively, listed as all grades (grade 3–4), were: pleural effusion 16% vs 23%, P=0.024 (5% vs 6%); peripheral edema 6% vs 13%, P=0.004 (<1%/1%); pericardial effusion <1% vs 4%, P=0.012 (0% vs 1%); neutropenia 85% vs 87% (65% vs 70%); thrombocytopenia 89% vs 92% (68% vs 70%). Dose reductions (24% vs 36%, P=0.002) and interruptions (47% vs 54%, P=0.105) were required less frequently for the 140-mg QD regimen, whereas dose escalations were more prevalent (33% vs 22%, P=0.005). Conclusions: Dasatinib 140 mg QD shows comparable hematologic and cytogenetic response and a trend for improved tolerability in relation to 70 mg BID. Further follow-up is ongoing to assess the long-term benefit of these two schedules in patients with ABP-CML or Ph(+) ALL; 1-year follow-up will be presented. [Table: see text] [Table: see text]
29
Kácsor, Enikő. "Modelling Bidding Behaviour on German Photovoltaic Auctions." Energies 14, no. 2 (January 19, 2021): 516. http://dx.doi.org/10.3390/en14020516.
Full textAbstract:
In this article renewable energy support allocation through different types of auctions are assessed. The applied methodological framework is auction theory, based on the rules governing the German photovoltaic (PV) Feed-in Premium (FIP) auctions. The work focuses on bidding strategies based on an extended levelised cost of electricity (LCOE) methodology, comparing two different set of rules: uniform price and pay-as-bid. When calculating the optimal bids an iteration is developed to find the Nash-equilibrium optimal bidding strategy. When searching for the bid function, not only strictly monotone functions, but also monotone functions are considered, extending the framework typically applied in auction theory modelling. The results suggest that the PV support allocation in the German auction system would be more cost efficient using the uniform pricing rule, since many participants bid above their true valuation in the pay-as-bid auction Nash-equilibrium. Thus from a cost minimising perspective, the application of uniform pricing rule would be a better policy decision.
30
Akinwande, Abayomi Adewale, Olanrewaju Seun Adesina, Adeolu Adesoji Adediran, Oluwatosin Abiodun Balogun, David Mukuro, Oluwayomi Peter Balogun, Kong Fah Tee, and M. Saravana Kumar. "Microstructure, Process Optimization, and Strength Response Modelling of Green-Aluminium-6061 Composite as Automobile Material." Ceramics 6, no. 1 (February 1, 2023): 386–415. http://dx.doi.org/10.3390/ceramics6010023.
Full textAbstract:
The use of ashes derived from various waste sources as supplements to synthesized ceramic reinforcement in metal matrices has been established. However, studies involving a combination of particulates from three different sources are rare. In a bid to further knowledge in this aspect of research and develop a green aluminium composite for automobile applications, the present investigation studied the implication of adding palm kernel shell ash (PKA), rice husk ash (RHA), and waste steel particles (STP) to the morphology and strength behaviour of Al-6061-T6 alloy. The experimental design was undertaken via the Box–Behnken design (BBD) of the response surface method. A 4% STP at a constant dose was mixed with PKA and RHA at varying proportions and stirring temperatures according to the BBD. The experimental outcome revealed that the responses were greatly influenced by microstructural evolution. From the surface plots, 2–4% RHA and PKA enhanced tensile and flexural strengths, while 4–6% led to a decline in strength. Meanwhile, 2–6% of the particles are favourable to the enhancement of tensile and compressive strengths and moduli. Temperatures between 700 and 800 °C favored response improvement, whereas temperatures between 800 and 900 °C were detrimental to responses. Developed regression models for the responses were validated to be good representations of the experimental outcomes. The optimum mix was obtained at 4.81% PKA, 5.41% RHA, and a stirring temperature of 803 °C. The validation experiment conducted portrayed reliable responses with <5% deviation from the predicted values, thereby certifying the models to be statistically fit for future predictions.
31
Smirnov, Evgeny Borisovich, and Svetlana Anatolievna Ershova. "Development of Construction Cost Assessment Methods during Preparation for Tender." Advanced Materials Research 1020 (October 2014): 854–58. http://dx.doi.org/10.4028/www.scientific.net/amr.1020.854.
Full textAbstract:
Successful development of a construction company under the market economical conditions depends on the number of contracts for construction works awarded to the company, usually on the competitive basis. The winner of a tender is chosen from the participants that have previously proved their qualification at the prequalification stage, on the basis of two criteria: bid price and construction period. Bid price is the key factor which is of the most importance to the client. It is based on contractor’s estimation of construction cost. The most common construction cost assessment methods use the valid estimate norms calculated on the basis of the averaged work costs which do not consider fluctuation of actual market prices for different kinds of resources and the chosen methods and technologies of facility construction. This paper aims to provide the basis for the development of accurate cost assessment method which is based on the actual market prices for all kinds of resources and on the methods and technologies of facility construction chosen be the contractor, rather than on the valid estimate norms. The main task therefore is the development of the key principles and sequence of construction cost assessment during preparation for tender. The offered assessment method is based on construction schedule illustrating the time association of all construction processes and is the basis for determination of the actual volume of the required resources and funds at each time point of facility construction. Given the many-sidedness of the arising problems, construction cost assessment should be conducted based on the following principles: construction schedule optimization; accounting of market cost of resources; generating the best plan of construction resource provision; cost minimization and financial flow optimization; risk accounting; project approach. Using these principles during assessment of facility construction cost within the framework of bid preparation allows increasing its competitive ability according to the main winner choice criteria – construction cost and periods.
32
Sun, Bo, Simin Li, Jingdong Xie, and Xin Sun. "IGDT-Based Wind–Storage–EVs Hybrid System Robust Optimization Scheduling Model." Energies 12, no. 20 (October 11, 2019): 3848. http://dx.doi.org/10.3390/en12203848.
Full textAbstract:
Wind power has features of uncertainty. When wind power producers (WPPs) bid in the day-ahead electricity market, how to deal with the deviation between forecasting output and actual output is one of the important topics in the design of electricity market with WPPs. This paper makes use of a non-probabilistic approach—Information gap decision theory (IGDT)—to model the uncertainty of wind power, and builds a robust optimization scheduling model for wind–storage–electric vehicles(EVs) hybrid system with EV participations, which can make the scheduling plan meet the requirements within the range of wind power fluctuations. The proposed IGDT robust optimization model first transforms the deterministic hybrid system optimization scheduling model into a robust optimization model that can achieve the minimum recovery requirement within the range of wind power output fluctuation, and comprehensively considers each constraint. The results show that the wind–storage–EVs hybrid system has greater operational profits and less impact on the safe and stable operation of power grids when considering the uncertainty of wind power. In addition, the proposed method can provide corresponding robust wind power fluctuation under different expected profits of the decision-maker to the wind–storage–EVs hybrid system.
33
Agrawala, Ramachandra, Prakash Kumar Hota, and Ranjan Kumar Mallick. "Optimal bidding of market players in competitive electricity markets based on a novel hybrid PSO-IGWO method." International Journal of Engineering & Technology 7, no. 2.12 (April 3, 2018): 399. http://dx.doi.org/10.14419/ijet.v7i2.12.11359.
Full textAbstract:
Strategic bidding is an important issue in the restructured electric marketplace. In an hour ahead actual power market having sealed bid auc-tion policy involving incomplete information of symmetrical and unsymmetrical nature have been addressed separately in the present work. Various constraints either equality type or inequality type have been properly analysed to model a market very close to a real one. Social welfare, where all the players individually benefitted is the prime objective. Hence, the bidding coefficients are to be selected very carefully. At present, the digital advancement supports each participant to optimize its desired objective through the optimization methods available so far. But, the proposed Particle Swarm Optimization-Improved Grey Wolf Optimization (PSO-IGWO) is a very novel hybrid method. Its supremacy compared to the other methods has been clearly evidenced by implementing in the present work. The standard IEEE-30 bus sys-tem and a practical 75 Bus Indian system have been considered to validate the effectiveness of the novel technique suggested and the excel-lent outputs evidence this fact on comparison with the results, of a very recently published article, found adopting GA optimization tech-nique [28].
34
Wang, Qi, Bin Lu, Xiaobo Dou, Yichao Sun, and Jin Liu. "Distribution Network Voltage Control Based on Coordinated Optimization of PV and Air-Conditioning." International Journal of Photoenergy 2018 (June 3, 2018): 1–7. http://dx.doi.org/10.1155/2018/2415289.
Full textAbstract:
This paper proposes a coordinated optimal control strategy of PV generators and air-conditioning loads, in order to handle the possible voltage beyond limit issues resulting from high penetration of PV generators in the distribution networks. This strategy is achieved via coordinately considering the node voltage sensitivity and the adjustment-compensation bid model, to improve the economy of the whole system. As a result, the shortage of the PVs’ reactive power control capability is compensated by the adjustable air-conditioning loads, so that the waste of the photovoltaic power can be reduced or even avoided. The case study using an IEEE standard 33-node system, which is further updated with the installation of 5 PV generators and 5 air-conditioning loads, validates the correctness and effectiveness of the proposed control strategy.
35
Dwijendra, Ngakan Ketut Acwin, Wongchai Anupong, Ahmed Majed Althahabi, Sabah Auda Abdulameer, Waleed Khalid Al-Azzawi, Mustafa Musa Jaber, Musaddak Maher Abdul Zahra, and Zuhair I. Al Mashhadani. "Optimal Dispatch of the Energy Demand in Electrical Distribution Grid with Reserve Scheduling." Environmental and Climate Technologies 27, no. 1 (January 1, 2023): 80–91. http://dx.doi.org/10.2478/rtuect-2023-0007.
Full textAbstract:
Abstract The operation of the electrical systems is a major problem for electrical companies’ subject to uncertainties threatening. In this study, the optimal management of the energy demand in the electrical distribution grid is done by interval optimization approach under electrical price uncertainty. The management of the energy demand is implemented via incentive-based modelling of the demand response programs (DRPs). The incentive-based modelling as reserve, and based on bid price for reduction of the electrical demand at peak hours is proposed. The interval optimization approach is used for the minimization of the electrical price uncertainty effects. The main objective in the proposed approach is minimizing operation cost; epsilon-constraint method is utilized to solve the problem. Finally, an electrical distribution grid has been used at various case studies to numerical simulation results and positive effects of the proposed modelling under uncertainties.
36
Lengwiler, Yvan, and Elmar Wolfstetter. "Auctions and corruption: An analysis of bid rigging by a corrupt auctioneer." Journal of Economic Dynamics and Control 34, no. 10 (October 2010): 1872–92. http://dx.doi.org/10.1016/j.jedc.2010.03.002.
Full text
37
Iyer, K. C., and Mohammed Sagheer. "Optimization of Bid-Winning Potential and Capital Structure for Build-Operate-Transfer Road Projects in India." Journal of Management in Engineering 28, no. 2 (April 2012): 104–13. http://dx.doi.org/10.1061/(asce)me.1943-5479.0000071.
Full text
38
Liu, Hong Yong, Gang Wu, and Yi Yang. "Study on Engineering Materials with Improvement of Carrying out Project Management Sand Table Experiment and Prospect of Sand Table." Advanced Materials Research 848 (November 2013): 35–38. http://dx.doi.org/10.4028/www.scientific.net/amr.848.35.
Full textAbstract:
The project management sand table simulates the whole process management from wining a bid to project completion from the angel of the contractor. In the present, majority of colleges and universities offer project management sand table class. Engineering materials as the main entity of sand table experiment, the optimization of engineering materials is related to the final results of the sand table experiment. This paper summarizes the experience from teaching process of sand class, points out some mistakes during the experiments and gives some advice to improve. At last, this paper forecasts the prospect of sand table.
39
Ren, Peng, Ruiyou Zhang, and Zhiyou Li. "Edge-side task scheduling: Auction mechanism and genetic algorithm based methods." Advances in Engineering Technology Research 4, no. 1 (March 8, 2023): 12. http://dx.doi.org/10.56028/aetr.4.1.12.2023.
Full textAbstract:
Edge computing is an emerging computing architecture. The scheduling and optimization of the tasks on the edge side of the smart factory can effectively reduce the processing delay and improve the utilization efficiency of servers. This study focuses on the problem of edge-side task scheduling with the goal of minimizing the maximum completion time of the tasks. A first-price sealed-bid auction based algorithm and a genetic algorithm with elite retention strategy are designed to solve the problem. The experimental results indicate that the auction-based scheduling algorithm has better real-time performances compared to the genetic algorithm.
40
Pro, Barbara, Jonathan E. Brammer, Carla Casulo, Eric Jacobsen, Monica Mead, Neha Mehta-Shah, Jasmine M. Zain, et al. "Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results." Blood 136, Supplement 1 (November 5, 2020): 38–39. http://dx.doi.org/10.1182/blood-2020-140412.
Full textAbstract:
Relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) is an aggressive lymphoma with a median overall survival (OS) of 6 months. Most approved therapies have overall response rates (ORR) of < 30%, low complete response (CR) rates, and short progression free survival (PFS). Duvelisib (DUV), a dual PI3K-δ,γ inhibitor, is FDA approved at 25 mg twice daily (BID) for the treatment of R/R chronic lymphocytic leukemia or small lymphocytic lymphoma after ≥ 2 lines of prior therapy and R/R follicular lymphoma after ≥ 2 prior systemic therapies, the latter based on accelerated approval. DUV monotherapy demonstrated an ORR of 50% in patients (pts) with R/R PTCL in a Phase 1 study across multiple subtypes (Horwitz, Blood 2018). In the Phase 2, open-label, multi-center, PRIMO trial of DUV in R/R PTCL, the initial results of the dose-optimization phase (N=33) showed a 54% ORR in the 75 mg BID (N=13) and 35% in the 25 mg BID (N=20) cohorts by investigator assessment (INV) , the primary endpoint (Horwitz, ASH 2019). We report mature dose-optimization results and the initial results of a planned preliminary assessment (N=20) of the dose-expansion (NCT03372057; supported by Verastem Oncology). In the dose-optimization phase, pts received DUV at 25 mg (Cohort 1) or 75 mg BID (Cohort 2). Pts were evaluable if they completed 1 cycle (28 days) of DUV and had ≥ 1 efficacy assessment. The dose-expansion phase is ongoing with a targeted enrollment of 100 pts; pts were eligible if they had histologically confirmed R/R PTCL after ≥2 cycles of a prior standard regimen and a CD4 lymphocyte count of ≥ 50/mm3 (0.05 x 109/L). Based on the initial dose-optimization results, it was determined pts will receive DUV starting at 75 mg BID for 2 cycles to achieve more rapid tumor control, followed by 25 mg to try to maintain long-term disease control and mitigate the potential for later onset toxicities. Pts were to be maintained on therapy continuously until progressive disease (PD) or unacceptable toxicity. For those at 25mg BID, it was permitted for the dose to be re-escalated to 75 mg BID if an assessment shows PD and the pt had not required a dose modification due to toxicity. The primary endpoint is ORR by an Independent Review Committee (IRC), and secondary endpoints include duration of response (DOR), PFS, OS, disease control rate, and safety; all analyses consisted of pts that received at least 1 dose of DUV. The statistical analysis plan was amended to take a preliminary assessment of ORR after approximately 20 pts were evaluated for response in the dose-expansion phase, consistent with the number of pts that were evaluated in the dose-optimization phase (Cohort 2). Dose-Optimization Phase Efficacy Update: As of the data cutoff, 2 pts (1 each cohort) remain on treatment. Efficacy data are summarized in Table 1. Of those pts that achieved a CR, 1 in each cohort proceeded to undergo stem cell transplant or consolidated radiation therapy with curative intent, and are censored in the DOR assessment . Dose-Expansion Phase Initial Summary: As of the data cutoff of 23 March 2020, a total of 25 pts have been dosed, 20 of whom underwent at least 1 disease response assessment (Table 1). Pts had a median age of 61 years (range, 21-86 years) and a median of 2 prior therapies (range, 1-6). Forty-five percent (9/20) of pts remain on treatment (5 responders, 3 with assessments not yet performed, 1 on treatment with stable disease);11 pts discontinued due to PD (n=7), adverse events (n=2) , or to under go transplant (n=2). Responses occurred in 8/20 pts: PTCL-NOS (4 CR, 1 partial response [PR]), ALCL (1 PR), AITL (1 CR) and SPTCL (1 CR). The most frequent adverse events seen were neutrophil count decreased (25%), ALT increased (21%), WBC decreased (21%) and lymphocyte count decreased (21%). In summary, the DUV data observed to date show consistent response rates in a R/R PTCL pt population. The safety profile observed in PRIMO to date is consistent with the current safety profile of DUV. The mature dose-optimization phase results demonstrated a median DOR of 12.2 months for the 75 mg BID cohort. The preliminary results from the PRIMO dose-expansion cohort (75 mg BID followed by 25 mg BID dosing) show an ORR of 40 % and CR rate of 30% (6/20) by INV assessment. These data support continued evaluation of DUV as a treatment option for R/R PTCL. Updated data from the planned interim analysis after 40 pts enroll (occurred June 2020) will be presented. Disclosures Pro: Verastem Oncology: Research Funding. Brammer:Bristol-Myers Squibb: Research Funding; Celgene: Research Funding; Seattle Genetics: Honoraria, Speakers Bureau; Kymera: Honoraria; Verastem Oncology: Other: Travel. Jacobsen:Takeda: Honoraria; Merck, Pharmacyclics, F. Hoffmann-LaRoche, Novartis: Research Funding; Acerta, AstraZeneca, Merck: Consultancy. Mehta-Shah:Corvus: Research Funding; Verastem: Research Funding; Celgene: Research Funding; Bristol Myers-Squibb: Research Funding; Genetech/Roche: Research Funding; C4 Therapeutics: Consultancy; Karyopharm Therapeutics: Consultancy; Innate Pharmaceuticals: Research Funding; Kyowa Hakko Kirin: Consultancy. Zain:Seattle Genetics: Research Funding; Kyowa Kirlin: Research Funding; Mundai Pharma: Research Funding. Zinzani:Immune Design: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sandoz: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen-Cilag: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celltrion: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Verastem: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kirin Kyowa: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; EUSA Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Servier: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; TG Therapeutics, Inc.: Honoraria, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Portola: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Eusapharma: Consultancy, Speakers Bureau; Kyowa Kirin: Consultancy, Speakers Bureau; Immune Design: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Lustgarten:Verastem Oncology: Current Employment, Current equity holder in publicly-traded company. Youssoufian:Verastem Oncology: Current Employment, Current equity holder in publicly-traded company. Horwitz:Janssen: Consultancy; GlaxoSmithKline: Consultancy; Daiichi Sankyo: Research Funding; C4 Therapeutics: Consultancy; Beigene: Consultancy; Portola: Consultancy, Research Funding; Mundipharma: Consultancy; Innate Pharma: Consultancy; Corvus: Consultancy; Trillium: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Millenium/Takeda: Consultancy, Research Funding; Kyowa Hakka Kirin: Consultancy, Research Funding; Infinity/Verastem: Research Funding; Forty Seven: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Aileron: Consultancy, Research Funding; ADCT Therapeutics: Consultancy, Research Funding; Vividion Therapeutics: Consultancy; Verastem: Consultancy, Research Funding; Myeloid Therapeutics: Consultancy; Miragen: Consultancy; Kura Oncology: Consultancy; ASTEX: Consultancy; Affirmed: Consultancy. OffLabel Disclosure: Duvelisib (DUV), a dual PI3K-δ,γ inhibitor, is FDA approved at 25 mg twice daily (BID) for the treatment of R/R chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 lines of prior therapy and R/R follicular lymphoma after at least 2 prior systemic therapies, the latter based on accelerated approval. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Duvelisib is not approved for Peripheral T-Cell Lymphoma. This study is investigating treatment or outcomes that have not received approval from a Health Authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a Health Authority.
41
Etyangat, A., P. Tiboti, M. Kayondo, and H. Bakamwesiga. "Optimization of recycled polyethylene terephthalate plastic bottle fibers in grasscrete." IOP Conference Series: Earth and Environmental Science 896, no. 1 (November 1, 2021): 012024. http://dx.doi.org/10.1088/1755-1315/896/1/012024.
Full textAbstract:
Abstract Cement and concrete production account for between 5% to 8% of global CO2. Waste PET plastic and glass waste have also brought about rapid environmental degradation. Glasscrete was developed with glass powder of fewer than 75 microns (has pozzolanic properties) that performed 14% better than concrete at 90 days. So, to further this effort, this experimental research considered the glass create C20 (at 10% cement replacement) and added PET fibers (of aspect ratio 25) at different percentages of 1%, 2%, 3%, and 4% the weight of cement in a bid to optimize the grasscrete performance and its ability to absorb PET waste. Glasscrete being extremely brittle alone, failed by cracking at all percentage PET additions, thus improving its safety factor. A 1% PET fiber addition to grasscrete exhibited the highest strength properties compared to other percentage additions while having a durability of 1.5% better than concrete. It is thus recommended for structural uses as it outperforms concrete. Despite this, a 1% fiber addition decreased grasscrete’s compressive strength by at least 3.5% at 28 days and 6% at 90 days but improved the flexural strength by 5.4% at 28 days and 0.8% at 90 days testing.
42
Li, Zun, and Michael P. Wellman. "Evolution Strategies for Approximate Solution of Bayesian Games." Proceedings of the AAAI Conference on Artificial Intelligence 35, no. 6 (May 18, 2021): 5531–40. http://dx.doi.org/10.1609/aaai.v35i6.16696.
Full textAbstract:
We address the problem of solving complex Bayesian games, characterized by high-dimensional type and action spaces, many (> 2) players, and general-sum payoffs. Our approach applies to symmetric one-shot Bayesian games, with no given analytic structure. We represent agent strategies in parametric form as neural networks, and apply natural evolution strategies (NES) [wierstra2014natural] for deep model optimization. For pure equilibrium computation, we formulate the problem as bi-level optimization, and employ NES in an iterative algorithm to implement both inner-loop best response optimization and outer-loop regret minimization. In simple games including first- and second-price auctions, it is capable of recovering known analytic solutions. For mixed equilibrium computation, we adopt an incremental strategy generation framework, with NES as strategy generator producing a finite sequence of approximate best-response strategies. We then calculate equilibria over this finite strategy set via a model-based optimization process. Both our pure and mixed equilibrium computation methods employ NES to efficiently search for strategies over the functional space, given only black-box simulation access to noisy payoff samples. We experimentally demonstrate the efficacy of all methods on two simultaneous sealed-bid auction games with distinct type distributions, and observe that the solutions exhibit qualitatively different behavior in these two environments.
43
Vazifedan, Mehdi, and Qiji Jim Zhu. "No-Arbitrage Principle in Conic Finance." Risks 8, no. 2 (June 19, 2020): 66. http://dx.doi.org/10.3390/risks8020066.
Full textAbstract:
In a one price economy, the Fundamental Theorem of Asset Pricing (FTAP) establishes that no-arbitrage is equivalent to the existence of an equivalent martingale measure. Such an equivalent measure can be derived as the normal unit vector of the hyperplane that separates the attainable gain subspace and the convex cone representing arbitrage opportunities. However, in two-price financial models (where there is a bid–ask price spread), the set of attainable gains is not a subspace anymore. We use convex optimization, and the conic property of this region to characterize the “no-arbitrage” principle in financial models with the bid–ask price spread present. This characterization will lead us to the generation of a set of price factor random variables. Under such a set, we can find the lower and upper bounds (supper-hedging and sub-hedging bounds) for the price of any future cash flow. We will show that for any given cash flow, for which the price is outside the above range, we can build a trading strategy that provides one with an arbitrage opportunity. We will generalize this structure to any two-price finite-period financial model.
44
Horwitz, Steven M., Neha Mehta-Shah, Barbara Pro, Eric D. Jacobsen, Carla Casulo, Jonathan E. Brammer, Jeff Haney, et al. "Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase." Blood 134, Supplement_1 (November 13, 2019): 1567. http://dx.doi.org/10.1182/blood-2019-121401.
Full textAbstract:
Introduction Relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) carries a poor prognosis, with most approved therapies having response rates of < 30% and limited progression-free survival (PFS). Duvelisib (DUV), a dual PI3K-δ,γ inhibitor, is FDA approved at 25 mg twice daily (BID) for the treatment of R/R chronic lymphocytic leukemia or small lymphocytic lymphoma after ≥ 2 lines of prior therapy and R/R follicular lymphoma after ≥ 2 prior systemic therapies. DUV exhibited potent activity against T-cell lymphoma cell lines in vitro, and DUV monotherapy at 25 or 75 mg BID demonstrated clinical activity in patients (pts) with R/R peripheral T-cell lymphoma (PTCL) in phase 1 studies [overall response rate (ORR), 50%] across multiple subtypes (Horwitz et al. Blood 2018; Horwitz et al. 2019 ICML). The phase 2 PRIMO trial was designed to determine an optimal regimen of DUV monotherapy in R/R PTCL and characterize the efficacy and tolerability of DUV in this disease. We report the results for the dose-optimization phase of the PRIMO trial (NCT03372057). Methods In the dose-optimization phase, pts with R/R PTCL, ECOG performance score of ≤ 2, and no history of allogeneic stem cell transplant were randomized to receive DUV 25 mg BID with an option for dose escalation (cohort 1) or DUV 75 mg BID (cohort 2) continuously until development of progressive disease or unacceptable toxicity (cycle = 28 days). The primary endpoint was investigator-assessed ORR, and secondary endpoints included duration of response and safety. Results A total of 33 pts (cohort 1, n = 20; cohort 2, n = 13) were treated in the dose-optimization phase (Table). Pts had a median of 1.5 years (range, 0.3-12.7 years) from initial diagnosis and a median of 2 prior therapies (range, 1-8). Patients were evaluable if they completed 1 cycle of DUV and had ≥ 1 efficacy assessment. Nonevaluable patients could be replaced. Response was assessed in the evaluable and overall populations. All patients in cohort 2 and 13 of 20 patients in cohort 1 were able to complete 1 cycle of therapy. Seven patients in cohort 1 discontinued therapy early due to disease progression and/or toxicity. Low CD4 counts (< 50 cells/mm3; Common Terminology Criteria for Adverse Events grade 4) were associated with early discontinuation of DUV. Most responses (cohort 1, 5/7; cohort 2, 6/7) were observed at the end of cycle 1. At a median follow-up of 20 weeks, the majority of responders (cohort 1, 4/7; cohort 2, 6/7) were still in response at the time of their last assessment. ORR as assessed by blinded independent central review could be determined for 31 patients and was 42% in cohort 1 and 67% in cohort 2. Table. Analysis Populations and Investigator-Assessed Response Pharmacokinetic analysis demonstrated a dose-related increase in exposure, with ≈ 2-fold increase in the steady-state exposure of DUV at the 75 vs 25 mg BID dosage, suggesting that adequate exposure can be more rapidly and reliably achieved with a higher dose of DUV. No differences were observed in pharmacodynamic markers (pAKT in monocytes and B cells) at 25 and 75 mg dose levels. The most common (≥ 3 patients) grade ≥ 3 adverse events (AEs) in all patients receiving DUV were neutropenia (7), thrombocytopenia (5), and sepsis (4), with disease progression, pneumonia, aspartate aminotransferase elevation, lymphopenia, dyspnea, and rash observed in 3 patients. Serious AEs occurring in ≥ 2 patients were colitis, pyrexia, disease progression, sepsis, pneumonia, hyponatremia, dyspnea, pneumonitis, and respiratory failure. Overall, 12% of pts receiving DUV discontinued due to an AE. Conclusions These findings confirm that both 25 and 75 mg BID starting dosages of DUV are clinically active in pts with R/R PTCL, with complete responses in both cohorts. There were no unexpected toxicities. Early progression was seen more frequently in the 25 mg cohort, and higher initial exposure may be important in aggressive diseases. The expansion phase of the PRIMO trial will investigate DUV starting at 75 mg BID for 2 cycles to achieve rapid tumor response, followed by 25 mg BID to maintain long-term disease control and mitigate the potential for later onset toxicity. Disclosures Horwitz: Miragen: Consultancy; Celgene: Consultancy, Research Funding; Aileron: Research Funding; Aileron: Research Funding; Seattle Genetics: Consultancy, Research Funding; ADCT Therapeutics: Research Funding; Corvus Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Kyowa Hakko Kirin: Consultancy; Astex: Consultancy; Affimed: Consultancy; Kura: Consultancy; Infinity/Verastem: Consultancy, Research Funding; Portola: Consultancy; Affimed: Consultancy; Celgene: Consultancy, Research Funding; Millennium/Takeda: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Innate Pharma: Consultancy; Millennium/Takeda: Consultancy, Research Funding; Astex: Consultancy; ADCT Therapeutics: Research Funding; Portola: Consultancy; Mundipharma: Consultancy; Aileron: Research Funding; Portola: Consultancy; Forty-Seven: Research Funding; Trillium: Research Funding; Aileron: Research Funding; Celgene: Consultancy, Research Funding; Millennium/Takeda: Consultancy, Research Funding; Kura: Consultancy; Seattle Genetics: Consultancy, Research Funding; Astex: Consultancy; Forty-Seven: Research Funding; Corvus Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; ADCT Therapeutics: Research Funding; Astex: Consultancy; Miragen: Consultancy; Kyowa Hakko Kirin: Consultancy; Millennium/Takeda: Consultancy, Research Funding; Affimed: Consultancy; Miragen: Consultancy; Mundipharma: Consultancy; Innate Pharma: Consultancy; Forty-Seven: Research Funding; Celgene: Consultancy, Research Funding; Innate Pharma: Consultancy; Innate Pharma: Consultancy; Mundipharma: Consultancy; Corvus Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Consultancy, Research Funding; Affimed: Consultancy; Kyowa Hakko Kirin: Consultancy; Trillium: Research Funding; Forty-Seven: Research Funding; Kyowa Hakko Kirin: Consultancy; Kura: Consultancy; Infinity/Verastem: Consultancy, Research Funding; Corvus Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Miragen: Consultancy; Trillium: Research Funding; Kura: Consultancy; Mundipharma: Consultancy; Infinity/Verastem: Consultancy, Research Funding; Trillium: Research Funding; Infinity/Verastem: Consultancy, Research Funding; Portola: Consultancy; ADCT Therapeutics: Research Funding. Mehta-Shah:Kiowa Hakka Kirin: Consultancy; Roche/Genentech: Research Funding; Bristol Myers Squibb: Research Funding; Verastem Pharmaceuticals: Research Funding; Celgene: Research Funding; Innate Pharmaceuticals: Research Funding. Pro:Takeda: Consultancy, Honoraria, Other: Travel Expenses; Celgene: Consultancy, Honoraria; Kyowa Hakka Kirin: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria, Other: Travel Expenses, Research Funding. Jacobsen:Pharmacyclics: Research Funding; Merck: Consultancy, Research Funding; Novartis: Research Funding; Takeda: Honoraria; Acerta: Consultancy; Astra-Zeneca: Consultancy; F. Hoffmann-LaRoche: Research Funding. Casulo:Celgene: Research Funding; Gilead: Honoraria, Other: Travel, accommodation, expenses; Roche: Other: Travel, accommodation, expenses. Brammer:Celgene: Research Funding; Seatlle Genetics: Honoraria, Speakers Bureau. Haney:Verastem Inc: Employment, Equity Ownership. Youssoufian:Verastem Oncology: Consultancy, Equity Ownership. Weaver:Verastem Oncology: Employment, Equity Ownership, Patents & Royalties: Inventor; Hillstream Biopharma: Consultancy, Equity Ownership; FemtoDx: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: Inventor. Baglio:Verastem Oncology: Employment. Narasimhan:Verastem: Employment, Equity Ownership. Zain:Spectrum: Consultancy; Seattle Genetics: Consultancy. OffLabel Disclosure: Duvelisib (DUV), a dual PI3K-delta,gamma inhibitor, is US FDA approved at 25 mg twice daily (BID) for the treatment of R/R chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 lines of prior therapy and R/R follicular lymphoma after at least two prior systemic therapies.
45
Sherman, Eric Jeffrey, Macarena Ines De La Fuente, Rona Yaeger, Frank Yung-Chin Tsai, Filip Janku, Nicholas A. Butowski, Carl E. Allen, et al. "Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): 3106. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3106.
Full textAbstract:
3106 Background: FORE8394 is a selective inhibitor of class 1 (V600) and 2 (activating non-V600) BRAF alterations that avoids paradoxical MAPK pathway activation. Consistent with the paradigm shift to optimal dosing vs identifying the maximal tolerated dose, integrated pharmacokinetic (PK), genomics, safety, and efficacy data, and exposure-response modeling were used to identify the recommended dose (RD). Methods: In a single arm phase 1/2a study, patients (pts) age ≥3 years with advanced solid or CNS tumors with BRAF alterations received FORE8394 900-3600 mg/day with or without the PK enhancer cobicistat (cobi) until progression. Efficacy pts had class 1 or 2 BRAF alterations & ≥1 post-baseline assessment (mITT); the BRAF V600 MAPKi naïve, non CRC subset provided a homogenous subset to also inform dose selection. PK was evaluated after single and repeated dosing. Results: To date, 110 pts (age range 4-86 years) received ≥1 dose of FORE8394; 58% had ≥2 prior lines of therapy, 25% had prior MAPKi. PK was independent of age or weight. Cobi increased FORE8394 exposure 2-3-fold. Exposure increased with dose, with less than proportional increase at doses >900 mg BID. Higher Cmax and trough levels were achieved with QD vs BID/TID. Objective (confirmed) responses were observed at all doses; however, objective response rate (ORR) was greatest (50%) at 900mg QD + cobi, with no further increases in ORR at higher doses. Dose-limiting toxicities were only observed at doses ≥1500 mg/day + cobi: 1500-1800 mg/day (4) and 2700-3600 mg/day (1). Similarly, treatment-emergent adverse events (TEAEs) ≥Grade 3 (G3) increased at the higher doses. Only 1 pt discontinued FORE8394 due to treatment-related AE (G3 bilirubin; 3600 mg/day). Conclusions: Based on the entirety of safety, PK, and efficacy data, the optimal RD of FORE8394 in Phase 2 is 900 mg QD + cobi in pts ≥10 years old. This achieved targeted efficacious exposures with robust antitumor activity and favorable safety. This dose optimization is consistent with current guidelines, avoids higher exposure that may lead to higher toxicity and compromise dose intensity. QD dosing also allows for a convenient dosing regimen. A Phase 2 study at the RD is ongoing in pts with recurrent V600E BRAF-mutated primary CNS tumors and advanced solid or CNS tumors with BRAF fusions. Clinical trial information: NCT02428712 . [Table: see text]
46
Lynch, Megan, Lei Hua, Chris Mix, and John B. Porter. "Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused: A Phase 3, Open-Label, Multicenter, Study (ACTIVATE-T) in Progress." Blood 134, Supplement_1 (November 13, 2019): 3526. http://dx.doi.org/10.1182/blood-2019-123107.
Full textAbstract:
Background: Pyruvate kinase (PK) deficiency is an under-recognized hereditary disease that causes lifelong hemolytic anemia. Mutations in the PKLR gene lead to reduced red cell PK (PK-R) enzyme activity, resulting in defective glycolysis and decreased lifespan of red blood cells. Mitapivat (AG-348) is a novel, first-in-class, oral, small-molecule allosteric activator of PK-R under clinical testing as the first targeted, disease-altering therapy for PK deficiency. In the DRIVE PK study (NCT02476916; a phase 2, open-label, dose-ranging trial in adults with PK deficiency who are not regularly transfused), twice-daily (BID) dosing with mitapivat for >6 months was well tolerated and induced rapid, durable responses (Grace et al. ASH 2017). As of July 14, 2017, 26 (50%) of 52 enrolled subjects had a maximum hemoglobin (Hb) increase of >1 g/dL. Among these 26 subjects, the mean maximum Hb increase was 3.4 g/dL, and 25 (96%) had ≥1 missense PKLR mutation. Based on these findings, mitapivat has entered phase 3 clinical development. The design of the ongoing phase 3 ACTIVATE-T study and its extension study are reported here, with an update on country/site activation and key early learnings on trial logistics in PK deficiency. Methods: ACTIVATE-T is a global, multicenter, open-label study (NCT03559699) to evaluate the efficacy and safety of mitapivat in regularly transfused adults with PK deficiency. Regularly transfused is defined as ≥6 transfusion episodes in the previous year. Subjects who are homozygous for the R479H mutation or have 2 non-missense mutations (without the presence of another missense mutation) in PKLR will be excluded, as will subjects with an average transfusion frequency of more than once every 3 weeks in the previous year. The study comprises an 8-week screening period, during which each subject's complete transfusion history from the prior 52 weeks is documented, followed by a 16-week dose optimization period and a 24-week fixed-dose period (Figure). During the dose optimization period, each subject will undergo individualized mitapivat dose optimization. All subjects will start on a dose of 5 mg BID, which may be increased twice over the course of 16 weeks (from 5 to 20 mg BID and from 20 to 50 mg BID). In the fixed-dose period, each subject will receive mitapivat at their optimized dose for 24 weeks. During the study, subjects will be transfused when their Hb reaches or falls below their individual transfusion trigger calculated from their transfusion history. The primary endpoint is the proportion of subjects who achieve a reduction in transfusion burden, defined as a reduction of ≥33% in the number of red blood cell units transfused during the 24 weeks of the fixed-dose period compared with the historical transfusion burden standardized to 24 weeks. Secondary endpoints include safety. All subjects who complete the study will have the opportunity to enroll in an open-label extension study (NCT03853798) in which all participants will receive mitapivat for up to 192 weeks. The ACTIVATE-T trial is enrolling globally. Disclosures Lynch: Agios: Employment, Equity Ownership. Hua:Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Mix:Agios: Employment, Equity Ownership. Porter:Bluebird bio: Consultancy, Honoraria; Silence therapeutics: Honoraria; Vifor: Honoraria; La Jolla: Honoraria; Protagonism: Honoraria; Celgene: Consultancy, Honoraria; Agios: Consultancy, Honoraria.
47
Polat, Gul, Harun Turkoglu, and Atilla Damci. "A Grading System-based Model for Detecting Unbalanced Bids during the Tendering Process." Periodica Polytechnica Architecture 50, no. 2 (June 4, 2019): 139–47. http://dx.doi.org/10.3311/ppar.12669.
Full textAbstract:
Unbalanced bidding is a common practice used in both unit price and lump sum contracts. Contractors may unbalance their bids in different forms for various reasons. The studies in the literature either focus on developing optimization models that assist contractors in winning contracts and maximizing profits of their bids through unbalancing or developing models that assist owners in detecting and/or preventing unbalanced bids during the bid evaluation stage. Unbalanced bidding is one of the most controversial subjects in the construction management literature and practice. Although there is no consensus on whether it is unethical or not, this practice is not usually for the benefit of owners. Therefore, owners have the right to reject the unbalanced bids and create a fair competition environment if they have a mechanism to detect it during the bid evaluation process. The main objective of this study is to propose a model, which consists of five different grading systems and helps owners in detecting unbalanced bids during the tendering process. In the proposed model, owners may either calculate the individual grades of each bidder or calculate the final score of each bidder by assigning different weights to these grading systems according to the project characteristics or their own needs. The final scores and bid prices of the contractors can be simultaneously evaluated. In order to demonstrate the applicability of the proposed model, an illustrative example is presented. It can be concluded that the proposed model can be effectively and easily used by owners for detecting unbalanced bids. This paper is the revised version of the paper that has been published in the proceedings of the Creative Construction Conference 2018 (Polat et al., 2018).
48
Subulan, Kemal, Adil Baykasoğlu, Derya Eren Akyol, and Gokalp Yildiz. "Metaheuristic-based simulation optimization approach to network revenue management with an improved self-adjusting bid price function." Engineering Economist 62, no. 1 (May 6, 2016): 3–32. http://dx.doi.org/10.1080/0013791x.2016.1174323.
Full text
49
Hughes, Timothy P., Marco Aurelio Salvino, Ong Tee Chuan, Alaa Elhaddad, Kudrat Abdulkadyrov, Jake Shortt, Hang Quach, et al. "Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study." Blood 126, no. 23 (December 3, 2015): 344. http://dx.doi.org/10.1182/blood.v126.23.344.344.
Full textAbstract:
Abstract Background: In the pivotal Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, frontline NIL 300 mg and 400 mg twice daily (BID) resulted in higher rates of deep molecular response and lower rates of disease progression than imatinib in pts with CML-CP. In the ENEST-Extending Molecular Responses (ENESTxtnd) study, the kinetics of molecular response to NIL 300 mg BID and novel dose optimization strategies were evaluated. Methods: ENESTxtnd was a 24 months (mo), phase 3b study of de novo pts with CML-CP within 6 mo of diagnosis. Primary endpoint was rate of major molecular response (MMR; BCR-ABL1 ≤ 0.1% on the International Scale [IS]) by 12 mo. Initial dose for all pts was NIL 300 mg BID. Dose escalation to NIL 400 mg BID was permitted for pts with suboptimal response (SoR) or treatment failure. Dose reduction to NIL 450 mg once daily (QD) was performed as required by the protocol; reescalation was permitted following adverse event (AE) improvement. Successful reescalation was defined as ≥ 4 weeks of NIL 300 mg BID with no dose adjustments for any AE. Rates of overall survival (OS; considering all deaths during the study) and progression-free survival (PFS; considering events during study treatment) were estimated by Kaplan-Meier analysis. Results: A total of 421 pts (median age, 48 y; males, 53.7%) were enrolled. Median time on study treatment was 23.7 mo; 328 pts (77.9%) completed 24 mo of treatment, and 93 pts (22.1%) discontinued early due to AEs (n = 43), consent withdrawal (n = 7), disease progression (n = 6), protocol deviation (n = 6), loss to follow-up (n = 5), death (n = 4), pregnancy (n = 2), or other reasons (n = 20). Of the 92 pts (21.9%) dose-escalated, 88 (20.9%) were dose-escalated due to lack of efficacy (SoR, 83, 19.7%; treatment failure, 5, 1.2%) and 4 due to dosing error; 11 pts were dose-escalated at 3 mo. Of the dose-escalated pts, 5 and 9 pts discontinued due to SoR and treatment failure, respectively. A total of 144 pts (34.2%) had dose reductions, dose reduction due to AEs were reported in 74 pts; 106 pts attempted to reescalate to NIL 300 mg BID, and 92 successfully reescalated. Median duration of exposure of all pts was 23.2 mo and median actual dose intensity was 598.8 mg/d (range, 150-760 mg/d). At 12 mo, 306, 33, 16, and 7 pts were on NIL 300 mg BID, 400 mg BID, 450 mg QD, and other doses respectively; 59 pts had discontinued prior to 12 mo. Of the 306 pts on NIL 300 mg BID at 12 mo, 136 did not have any dose modification (interruption/reduction/escalation) prior to 12 mo and 170 had ≥1 dose modification. Of the 170 pts, 88 had ≥ 1 dose reduction followed by reescalation to 300 mg BID. Among the 16 pts on a reduced dose at 12 mo, 4 later re-escalated to NIL 300 mg BID. The cumulative MMR rate (95% CI) was 70.8% (66.2%-75.1%) by 12 mo and 81.0% (76.9%-84.6%) by 24 mo (figure). Of the 88 pts with dose escalation due to lack of efficacy, 63.6% achieved MMR by 24 mo (Table 1). Of the 144 pts with dose reduction, 75.7% achieved MMR by 24 mo, including 78 of 92 pts (85%) who successfully reescalated to NIL 300 mg BID (Table 2). The cumulative rate of complete cytogenetic response by 24 mo was 74.1 %. Ten pts had PFS events on treatment (progression, n = 6; death, n = 4), and 9 deaths were reported at any time on study and during follow-up 2 due to CML; 1 each due to cardiorespiratory arrest, intestinal infarction, acute leukemia, increased intracranial pressure, accident, suicide, and unknown). The estimated rates (95% CI) of PFS and OS at 24 mo were 97.0% (95.1%-98.8%) and 97.6% (96.1%-99.2%), respectively. The most common nonhematologic drug-related AEs of any grade were rash (15.4%), headache (10.5%), and nausea (10.2%), and new or worsening grade 3/4 laboratory abnormalities were lipase abnormalities (14.5%), neutropenia (11.9%), and thrombocytopenia (10.5%). Cardiovascular events were observed in 19 pts (4.5%), including ischemic heart disease (n = 14), ischemic cerebrovascular events (n = 1), and peripheral artery disease (n = 5). Conclusion: Dose-optimized frontline NIL resulted in rapid reductions in BCR-ABL1IS levels andvery few progressions or deaths. Most pts achieved MMR by 24 mo, including > 60% of pts who were dose-escalated due to lack of efficacy and > 80% of pts who were successfully reescalated after dose reduction. The safety profile of NIL was consistent with previous studies. These results support the use of NIL 300 mg BID, with dose optimization as necessary, in pts with newly diagnosed CML-CP. Disclosures Hughes: ARIAD: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Off Label Use: The indicated label for newly diagnosed CML chronic phase patients is 300 mg twice daily. This abstract discusses modifications of this dose.. Salvino:Novartis: Research Funding. Shortt:Novartis, Bristol Meyers Squibb: Honoraria, Other: Sponsorship to attend conferences, Speakers Bureau. Quach:Celgene Corp, ONYX, Janssen, Takeda, Novartis, BMS: Honoraria, Research Funding. Pavlovsky:Novartis - Bristol: Speakers Bureau. Louw:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Unrestricted educational grant, Research Funding, Speakers Bureau. Shih:Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding. Turkina:Novartis International AG: Consultancy; Pfizer: Consultancy; Bristol-Myers Squibb: Consultancy. Meillon:Novartis, Bayer, BMS, Pfizer, AMGEN: Honoraria, Speakers Bureau. Jin:Novartis: Employment. Khanna:Novartis: Employment. Dalal:Novartis: Employment, Equity Ownership. Lipton:Ariad: Equity Ownership, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.
50
Messer, Kent D., and William L. Allen. "Applying Optimization and the Analytic Hierarchy Process to Enhance Agricultural Preservation Strategies in the State of Delaware." Agricultural and Resource Economics Review 39, no. 3 (October 2010): 442–56. http://dx.doi.org/10.1017/s1068280500007437.
Full textAbstract:
Using agricultural preservation priorities derived from an analytical hierarchy process by 23 conservation experts from 18 agencies in the state of Delaware, this research uses weighted benefit measures to evaluate the historical success of Delaware's agricultural protection fund, which spent nearly $100 million in its first decade. This research demonstrates how these operation research techniques can be used in concert to address relevant conservation questions. Results suggest that the state's sealed-bid-offer auction, which determines the yearly conservation selections, is superior to benefit-targeting approaches frequently employed by conservation organizations, but is inferior to the optimization technique of binary linear programming that could have provided additional benefits to the state, such as 12,000 additional acres worth an estimated $25 million.